Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec 6;11(23):7240.
doi: 10.3390/jcm11237240.

Current Medical and Surgical Treatment of Hidradenitis Suppurativa-A Comprehensive Review

Lennart Ocker  1 , Nessr Abu Rached  1 , Caroline Seifert  1 , Christina Scheel  1 , Falk G Bechara  1
Affiliations
Review

Current Medical and Surgical Treatment of Hidradenitis Suppurativa-A Comprehensive Review

Lennart Ocker et al. J Clin Med. .

Abstract

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease presenting with recurrent inflammatory lesions in intertriginous body regions. HS has a pronounced impact on patients' quality of life and is associated with a variety of comorbidities. Treatment of HS is often complex, requiring an individual approach with medical and surgical treatments available. However, especially in moderate-to-severe HS, there is an urgent need for new treatment approaches. In recent years, increased research has led to the identification of new potential therapeutic targets. This review aims to give a comprehensive and practical overview of current treatment options for HS. Furthermore, the clinically most advanced novel treatment approaches will be discussed.

Keywords: acne inversa; adalimumab; dermatology; hidradenitis suppurativa; inflammation; small molecules; targeted therapy; treatment.

PubMed Disclaimer

Conflict of interest statement

F.G.B. has received honoraria for participation in advisory boards, in clinical trials and/or as a speaker from AbbVie Inc., AbbVie Deutschland GmbH & Co. KG, Boehringer Ingelheim Pharma GmbH & Co. KG, Novartis Pharma GmbH, UCB Pharma, Incyte Corporation and JanssenCilag GmbH, MoonLake. The other authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

References

    1. Garg A., Kirby J.S., Lavian J., Lin G., Strunk A. Sex- and Age-Adjusted Population Analysis of Prevalence Estimates for Hidradenitis Suppurativa in the United States. JAMA Dermatol. 2017;153:760–764. doi: 10.1001/jamadermatol.2017.0201. - DOI - PMC - PubMed
    1. Theut Riis P., Pedersen O.B., Sigsgaard V., Erikstrup C., Paarup H.M., Nielsen K.R., Burgdorf K.S., Hjalgrim H., Rostgaard K., Banasik K., et al. Prevalence of Patients with Self-Reported Hidradenitis Suppurativa in a Cohort of Danish Blood Donors: A Cross-Sectional Study. Br. J. Dermatol. 2019;180:774–781. doi: 10.1111/bjd.16998. - DOI - PubMed
    1. Jfri A., Nassim D., O’Brien E., Gulliver W., Nikolakis G., Zouboulis C.C. Prevalence of Hidradenitis Suppurativa: A Systematic Review and Meta-Regression Analysis. JAMA Dermatol. 2021;157:924–931. doi: 10.1001/jamadermatol.2021.1677. - DOI - PMC - PubMed
    1. Jemec G.B., Heidenheim M., Nielsen N.H. The Prevalence of Hidradenitis Suppurativa and Its Potential Precursor Lesions. J. Am. Acad. Dermatol. 1996;35:191–194. doi: 10.1016/S0190-9622(96)90321-7. - DOI - PubMed
    1. Mac Mahon J., Kirthi S., Byrne N., O’Grady C., Tobin A. An Update on Health-Related Quality of Life and Patient-Reported Outcomes in Hidradenitis Suppurativa. Patient Relat. Outcome Meas. 2020;11:21–26. doi: 10.2147/PROM.S174299. - DOI - PMC - PubMed

LinkOut - more resources